Paxlovid cuts COVID hospitalization, death risk and speeds symptom relief, studies find Overall, the risk of developing 28 out of 36 long-COVID symptoms lessened when vaccines were effective. CIDRAP

New findings from two studies have tied use of the antiviral drug nirmatrelvir-ritonavir (Paxlovid) to a reduction in COVID-19 hospitalizations and death, as well as to faster resolution of symptoms and less use of healthcare resources.

Benefit seen only in older patients

As H5N1 bird flu continues to spread around the US, health officials recently found that 7 percent of dairy workers tested on farms in two states had evidence of recent infection — and some had signs of infection even when they didn’t feel sick.